A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

• Status: Recruiting
• Trial end date: 2023-05-20
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC

Criteria

Inclusion Criteria:

• Confirmed adenocarcinoma of the prostate which has spread to other body parts

• Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy

• Measurable or evaluable disease

• Concurrent use of any other anticancer treatment must be discontinued for at least 2 weeks before the first dose of study drug

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Prior surgical removal of testicles; or, for participants who have not undergone surgical removal of testicles, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog

Exclusion Criteria:

Disease conditions

• Active central nervous system (CNS) involvement

• Toxicity related to prior anticancer therapy has not adequately recovered

Prior/Concomitant Therapy

• Prior treatment with human kallikrein (KLK) 2-targeted therapy

• Received, or are receiving, medications that suppress the immune system within 3 days prior to the first dose of study drug

• Received or plans to receive any live, attenuated vaccine within 4 weeks prior to the first dose of study drug

Prior/Concurrent Medical Conditions

• Diagnosis of cancer other than prostate cancer within 2 years prior to the first dose of study drug

• Solid organ or bone marrow transplantation

• Major clotting diseases within one month prior to the first dose of study drug

• Active autoimmune disease within 12 months prior to the first dose of study drug

• Active infection

• Major diseases of heart and blood vessels within 6 months prior to the first dose of study drug

• Clinically significant lung diseases

• Active or chronic hepatitis B or hepatitis C infection

• Known positive test result for human immunodeficiency virus (unless stable on antiretroviral therapy with undetectable viral load)

• Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment